Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
NRG1 type I dependent autoparacrine stimulation of Schwann cells in onion bulbs of peripheral neuropathies.
Fledrich R, Akkermann D, Schütza V, Abdelaal TA, Hermes D, Schäffner E, Soto-Bernardini MC, Götze T, Klink A, Kusch K, Krueger M, Kungl T, Frydrychowicz C, Möbius W, Brück W, Mueller WC, Bechmann I, Sereda MW, Schwab MH, Nave KA, Stassart RM. Fledrich R, et al. Among authors: gotze t. Nat Commun. 2019 Apr 1;10(1):1467. doi: 10.1038/s41467-019-09385-6. Nat Commun. 2019. PMID: 30931926 Free PMC article.
Publisher Correction: NRG1 type I dependent autoparacrine stimulation of Schwann cells in onion bulbs of peripheral neuropathies.
Fledrich R, Akkermann D, Schütza V, Abdelaal TA, Hermes D, Schäffner E, Soto-Bernardini MC, Götze T, Klink A, Kusch K, Krueger M, Kungl T, Frydrychowicz C, Möbius W, Brück W, Mueller WC, Bechmann I, Sereda MW, Schwab MH, Nave KA, Stassart RM. Fledrich R, et al. Among authors: gotze t. Nat Commun. 2019 Apr 16;10(1):1840. doi: 10.1038/s41467-019-09886-4. Nat Commun. 2019. PMID: 30992451 Free PMC article.
Hyperactivity is a Core Endophenotype of Elevated Neuregulin-1 Signaling in Embryonic Glutamatergic Networks.
Götze T, Soto-Bernardini MC, Zhang M, Mießner H, Linhoff L, Brzózka MM, Velanac V, Dullin C, Ramos-Gomes F, Peng M, Husseini H, Schifferdecker E, Fledrich R, Sereda MW, Willig K, Alves F, Rossner MJ, Nave KA, Zhang W, Schwab MH. Götze T, et al. Schizophr Bull. 2021 Aug 21;47(5):1409-1420. doi: 10.1093/schbul/sbab027. Schizophr Bull. 2021. PMID: 33871014 Free PMC article.
Factor XII signaling via uPAR-integrin β1 axis promotes tubular senescence in diabetic kidney disease.
Elwakiel A, Gupta D, Rana R, Manoharan J, Al-Dabet MM, Ambreen S, Fatima S, Zimmermann S, Mathew A, Li Z, Singh K, Gupta A, Pal S, Sulaj A, Kopf S, Schwab C, Baber R, Geffers R, Götze T, Alo B, Lamers C, Kluge P, Kuenze G, Kohli S, Renné T, Shahzad K, Isermann B. Elwakiel A, et al. Among authors: gotze t. Nat Commun. 2024 Sep 11;15(1):7963. doi: 10.1038/s41467-024-52214-8. Nat Commun. 2024. PMID: 39261453 Free PMC article.
Rare HCV subtypes and retreatment outcomes in a cohort of European DAA-experienced patients.
Dietz J, Graf C, Berg CP, Port K, Deterding K, Buggisch P, Peiffer KH, Vermehren J, Dultz G, Geier A, Reiter FP, Bruns T, Schattenberg JM, Durmashkina E, Gustot T, Moreno C, Trauth J, Discher T, Fischer J, Berg T, Kremer AE, Müllhaupt B, Zeuzem S, Sarrazin C; European HCV Resistance Study Group. Dietz J, et al. JHEP Rep. 2024 Mar 25;6(7):101072. doi: 10.1016/j.jhepr.2024.101072. eCollection 2024 Jul. JHEP Rep. 2024. PMID: 39006503 Free PMC article.
FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN).
Isfort S, von Bubnoff N, Al-Ali HK, Becker H, Götze T, le Coutre P, Griesshammer M, Moskwa C, Wohn L, Riedel J, Palandri F, Manz K, Hochhaus A, Döhner K, Heidel FH. Isfort S, et al. Among authors: gotze t. Ann Hematol. 2024 Aug;103(8):2775-2785. doi: 10.1007/s00277-024-05867-w. Epub 2024 Jul 5. Ann Hematol. 2024. PMID: 38967662 Free PMC article. Clinical Trial.
Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trial.
Vogel A, Saborowski A, Wenzel P, Wege H, Folprecht G, Kretzschmar A, Schütt P, Jacobasch L, Ziegenhagen N, Boeck S, Zhang D, Kanzler S, Belle S, Mohm J, Gökkurt E, Lerchenmüller C, Graeven U, Pink D, Götze T, Kirstein MM. Vogel A, et al. Among authors: gotze t. Lancet Gastroenterol Hepatol. 2024 Aug;9(8):734-744. doi: 10.1016/S2468-1253(24)00119-5. Epub 2024 Jun 10. Lancet Gastroenterol Hepatol. 2024. PMID: 38870977 Free article. Clinical Trial.
52 results